Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




Automated NfL Assay Supports Monitoring of Neurological Disorders

By LabMedica International staff writers
Posted on 27 Mar 2026

Neuroaxonal injury occurs across a wide range of neurological disorders and remains difficult to monitor noninvasively over time. More...

Blood-based measurement of neurofilament light chain (NfL) provides a biologically meaningful indicator when interpreted using age-adjusted reference values and longitudinal trends. A new fully automated blood assay has now received CE certification, enabling standardized, quantitative measurement of NfL in plasma and serum for use in clinical laboratories.

Fujirebio Europe N.V. (Ghent, Belgium) has obtained a CE Certificate for the Lumipulse G NfL Blood assay under Regulation (EU) 2017/746 on in vitro diagnostic medical devices. The assay is designed for use on the Lumipulse G system and provides a quantitative result intended to support neurological evaluation. The certification extends the company’s neuro-focused test menu on its automated platform.

The Lumipulse G NfL Blood assay uses chemiluminescent enzyme immunoassay (CLEIA) methodology to detect and quantify NfL in human plasma and serum. By automating the workflow, the assay enables standardized processing and readout suitable for high-throughput laboratory environments. The CLEIA format supports sensitive detection aligned with routine clinical operations.

NfL is a marker of neuroaxonal injury that can support disease monitoring, prognosis, and treatment evaluation across a wide range of neurological conditions, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and traumatic brain injury (TBI). Its clinical utility depends on context-specific interpretation, including age-adjusted reference ranges, defined clinical decision thresholds, and longitudinal tracking. Elevated NfL levels reflect axonal damage across neurodegenerative disorders of inflammatory, vascular, infectious, and traumatic origin, largely independent of the underlying disease mechanism.

“While our assay menu already features many powerful disease-specific biomarkers, NfL marks a major breakthrough: our first CE-marked blood test that empowers clinicians with insights across a wide range of neurological disorders,” said Christiaan De Wilde, CEO at Fujirebio Europe N.V.

“We are excited to bring this test to our customers, further expanding our comprehensive portfolio of fully automated neurological disease testing solutions on the LUMIPULSE G platform. We continue to partner with organizations and clinical experts across the world to enable earlier, easier and more complete neurological disease diagnostic tools,” said De Wilde.

Related Links
Fujirebio


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.